BRIEF-Millendo Therapeutics - Exploring Expanded Range Of Strategic Alternatives To Maximize Its Assets

Reuters2021-01-06

Jan 5 (Reuters) - Millendo Therapeutics Inc :

* MILLENDO THERAPEUTICS - EXPLORING EXPANDED RANGE OF STRATEGIC ALTERNATIVES TO MAXIMIZE ITS ASSETS

* MILLENDO THERAPEUTICS INC - BOARD OF DIRECTORS HAS DECIDED TO DISCONTINUE FURTHER INVESTMENT IN MLE-301

* MILLENDO THERAPEUTICS - DATA FROM MLE-301 PHASE 1 STUDY DO NOT SUPPORT CONTINUING ITS DEVELOPMENT IN TARGET POPULATION OF PERI-, POST-MENOPAUSAL WOMEN

* MILLENDO THERAPEUTICS INC - INTENDS TO REVIEW ITS OPERATING COSTS AND MAY PLAN FOR A REDUCTION IN ITS WORKFORCE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2101643645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-01-06 00:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2101643645","market":"us","top_or_hot":-1,"title":"BRIEF-Millendo Therapeutics - Exploring Expanded Range Of Strategic Alternatives To Maximize Its Assets","media":"Reuters","content":"<html><body><p>Jan 5 (Reuters) - <a href=\"https://laohu8.com/S/MLND\">Millendo Therapeutics Inc</a>   :</p><p>   * MILLENDO THERAPEUTICS - EXPLORING EXPANDED RANGE OF STRATEGIC ALTERNATIVES TO MAXIMIZE ITS ASSETS</p><p>   * MILLENDO THERAPEUTICS INC - BOARD OF DIRECTORS HAS DECIDED TO DISCONTINUE FURTHER INVESTMENT IN MLE-301</p><p>   * MILLENDO THERAPEUTICS - DATA FROM MLE-301 PHASE 1 STUDY DO NOT SUPPORT CONTINUING ITS DEVELOPMENT IN TARGET POPULATION OF PERI-, POST-MENOPAUSAL WOMEN</p><p>   * MILLENDO THERAPEUTICS INC - INTENDS TO REVIEW ITS OPERATING COSTS AND MAY PLAN FOR A REDUCTION IN ITS WORKFORCE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Millendo Therapeutics - Exploring Expanded Range Of Strategic Alternatives To Maximize Its Assets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Millendo Therapeutics - Exploring Expanded Range Of Strategic Alternatives To Maximize Its Assets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-01-06 00:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 5 (Reuters) - <a href=\"https://laohu8.com/S/MLND\">Millendo Therapeutics Inc</a>   :</p><p>   * MILLENDO THERAPEUTICS - EXPLORING EXPANDED RANGE OF STRATEGIC ALTERNATIVES TO MAXIMIZE ITS ASSETS</p><p>   * MILLENDO THERAPEUTICS INC - BOARD OF DIRECTORS HAS DECIDED TO DISCONTINUE FURTHER INVESTMENT IN MLE-301</p><p>   * MILLENDO THERAPEUTICS - DATA FROM MLE-301 PHASE 1 STUDY DO NOT SUPPORT CONTINUING ITS DEVELOPMENT IN TARGET POPULATION OF PERI-, POST-MENOPAUSAL WOMEN</p><p>   * MILLENDO THERAPEUTICS INC - INTENDS TO REVIEW ITS OPERATING COSTS AND MAY PLAN FOR A REDUCTION IN ITS WORKFORCE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2101643645","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2101643645","pubTimestamp":1609864622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 5 (Reuters) - Millendo Therapeutics Inc   :   * MILLENDO THERAPEUTICS - EXPLORING EXPANDED RANGE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BRIEF-Millendo Therapeutics-探索扩大的战略选择范围以最大化其资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLND":0.9},"content_text":"Jan 5 (Reuters) - Millendo Therapeutics Inc   :   * MILLENDO THERAPEUTICS - EXPLORING EXPANDED RANGE OF STRATEGIC ALTERNATIVES TO MAXIMIZE ITS ASSETS   * MILLENDO THERAPEUTICS INC - BOARD OF DIRECTORS HAS DECIDED TO DISCONTINUE FURTHER INVESTMENT IN MLE-301   * MILLENDO THERAPEUTICS - DATA FROM MLE-301 PHASE 1 STUDY DO NOT SUPPORT CONTINUING ITS DEVELOPMENT IN TARGET POPULATION OF PERI-, POST-MENOPAUSAL WOMEN   * MILLENDO THERAPEUTICS INC - INTENDS TO REVIEW ITS OPERATING COSTS AND MAY PLAN FOR A REDUCTION IN ITS WORKFORCESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2101643645","isCrawlerRequest":true}